Ecovyst Shares Fall Following Mixed Q2 Results, Guides Full-year Outlook In-Line With Estimates-March 2024-www.financetom.com

Ecovyst Shares Fall Following Mixed Q2 Results, Guides Full-year Outlook In-Line With Estimates

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ecovyst Shares Fall Following Mixed Q2 Results, Guides Full-year Outlook In-Line With Estimates

Aug 7, 2025 9:11 AM

11:48 AM EDT, 08/07/2025 (MT Newswires) -- Ecovyst's ( ECVT ) shares fell 2.6% in recent Thursday trading after the company reported mixed Q2 results and updated its full-year outlook.

The company reported Q2 adjusted earnings of $0.12 per diluted share, the same as the year-prior quarter. That beat the estimates of analysts surveyed by FactSet for $0.10.

Revenue for the quarter ended June 30 rose to $200.1 million from $182.8 million, a year earlier. Analysts surveyed by FactSet expected $204.6 million.

The company said it now expects full-year 2025 adjusted income of $0.52 to $0.68 per diluted share, versus its previous guidance of $0.50 to $0.70 and the FactSet estimate of $0.63.

Full-year 2025 revenue is now expected to range between $795 million and $835 million, compared to its previous outlook of $785 million to $845 million. FactSet projects $797.9 million.

For Q3, the company expects adjusted EBITDA between $62 million and $72 million.

Price: 8.18, Change: -0.22, Percent Change: -2.56

Previous page： AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance Next page： Why Is American Airlines Stock Seeing Blue Skies Today?

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

Apr 25, 2024

Thursday, AstraZeneca Plc ( AZN ) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion. This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines. The company’s adjusted EPADS reached $1.03, missing the consensus of $1.22. Also Read: AstraZeneca Hikes Annual Dividend By 7%...

Why Is American Airlines Stock Seeing Blue Skies Today?

Apr 25, 2024

American Airlines Group Inc. ( AAL ) shares are trading higher after the company reported first-quarter financial results and issued second-quarter adjusted EPS guidance with a midpoint above estimates. Total revenue increased 3.1% to $12.57 billion, just missing estimates of $12.60 billion. Adjusted operating margin stood at 0.6% in the first quarter vs. 3.7% a year ago. The company reported an adjusted EPS loss of...

PG&E beats quarterly profit view, raises annual forecast

Apr 25, 2024

April 25 (Reuters) - Power company PG&E Corp ( PCG ) beat Wall Street estimates for first-quarter profit and raised its full-year earnings forecast on Thursday, helped by lower operating expenses, wildfire-related costs and higher tariffs. Last year, California Public Utilities Commission (CPUC) voted on a rise in the utility's base rate case that would raise customer bills by nearly...

ASE Technology Holding's Q1 Earnings Fall, Revenue Increases

Apr 25, 2024

09:03 AM EDT, 04/25/2024 (MT Newswires) -- ASE Technology Holding ( ASX ) reported Q1 earnings Thursday of 1.28 New Taiwan dollars ($0.04) per diluted share, down from 1.30 New Taiwan dollars a year earlier. Analysts polled by Capital IQ expected 1.40 New Taiwan dollars. Revenue for the quarter ended March 31 was about 132.80 billion New Taiwan dollars, up...